Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention;La influencia de los métodos de presentación de los resultados en ensayos clínicos sobre la eficacia de una intervención y la intencón de prescribir fármacos para la prevención cardiovascular

Revista Espanola de Cardiologia

Volumn 55, Issue 10, 2002, Pages 1042-1051

  Brotons, Carlos ^a   Moral, Irene ^a   Ribera, Aida ^a   Cascant, Purificación ^a   Iglesias, Manuel ^b   Permanyer Miralda, Gaietà ^a   Ferreira González, Ignacio ^a   Soler Soler, Jordi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUT CATALÀ DE LA SALUT   (Spain)

Author keywords

Clinical trials; Epidemiology; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; ISCHEMIC HEART DISEASE; MEASUREMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDICAL SPECIALIST; PRIMARY PREVENTION; PUBLISHING; QUESTIONNAIRE; RANDOMIZATION; RATING SCALE; RISK MANAGEMENT; SECONDARY PREVENTION;

EID: 18744422769     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(02)76754-7     Document Type: Article

References (19)

1. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
2. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992; 117:916-21.
3. Forrow L, Taylor WC, Arnold R. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med 1992;92:121-4.
4. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994;309:761-4.
5. Bobbio M, Dernichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians' willingness to prescribe. Lancet 1994;343:1209-11.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1307-17.
7. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
8. Steering Committee of the Physicians' health study research group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-35.
9. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
10. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
11. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986;105:429-35.
12. SPSS. SPSS/PC+V3.0 System Chicago: SPSS, 1988.
13. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6.
14. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists' practices compared with practice guideline: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432-6.
15. Rogers WJ, Bowlyby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-14.
16. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18:1569-82.
17. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001;22:554-72.
18. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997;80:45H-52H.
19. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM. Discontinuation of antihyperlipidernic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.